1. Home
  2. LENZ
  3. LENZ News

Latest LENZ Therapeutics Inc. (LENZ) News on October 23, 2025

Companies Like LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Invest In Growth
LENZ

Simply Wall St.

22 days ago

Companies Like LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Invest In Growth

LENZ

Argus Research

a month ago

Daily – Vickers Top Buyers & Sellers for 09/23/2025

Jim Cramer Says “LENZ Therapeutics Has a Promising Story”
LENZ

Insider Monkey

a month ago

Jim Cramer Says “LENZ Therapeutics Has a Promising Story”

LENZ

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 06/23/2025

LENZ Therapeutics to Present at Upcoming Investor Conferences
LENZ

GlobeNewswire

5 months ago

LENZ Therapeutics to Present at Upcoming Investor Conferences

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
LENZ

GlobeNewswire

5 months ago

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
LENZ

GlobeNewswire

6 months ago

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
LENZ

GlobeNewswire

6 months ago

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
LENZ

GlobeNewswire

6 months ago

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
LENZ

GlobeNewswire

7 months ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
LENZ

GlobeNewswire

7 months ago

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
LENZ

GlobeNewswire

7 months ago

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

LENZ Therapeutics to Host Commercial Day on April 15, 2025
LENZ

GlobeNewswire

8 months ago

LENZ Therapeutics to Host Commercial Day on April 15, 2025

LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ

GlobeNewswire

8 months ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k
LENZ

Simply Wall St.

8 months ago

LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k

We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely
LENZ

Simply Wall St.

a year ago

We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely

LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ

GlobeNewswire

a year ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

LENZ Therapeutics Reports Third Quarter 2024 Financial Results
LENZ

GlobeNewswire

a year ago

LENZ Therapeutics Reports Third Quarter 2024 Financial Results

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
LENZ

GlobeNewswire

a year ago

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
LENZ

GlobeNewswire

a year ago

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Lenz Therapeutics announces FDA acceptance of NDA for LNZ100
LENZ

TipRanks

a year ago

Lenz Therapeutics announces FDA acceptance of NDA for LNZ100

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences

LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment
LENZ

Simply Wall St.

a year ago

LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital

We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth
LENZ

Simply Wall St.

a year ago

We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

LENZ

GlobeNewswire

a year ago

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
LENZ

Business Wire

2 years ago

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
LENZ

Business Wire

2 years ago

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Share on Social Networks: